Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 2

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy

NCT07600736 · tracked via the Priya Life Science USA tracker
Sponsor
Actio Biosciences, Inc
Phase
Phase 2
Started
2026-05-18
Last updated
2026-10-15

Condition(s) studied

KCNT1-Related Epilepsy

Investigational drug(s) / intervention(s)

ABS-1230 →Placebo

ABS-1230: Daily

Placebo: Daily

Study summary

This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy

Eligibility

Sex
ALL
Min age
1 Month
Max age
21 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 1 month to \<22 years * Clinician-confirmed diagnosis of KCNT1-related epilepsy * Has an average of at least 4 countable motor seizures per week * Is taking no more than 6 antiseizure medications (ASM) and is able to keep stable doses of ASMs for the duration of Part 1 or Part 2 Exclusion Criteria: * Is currently taking phenytoin, carbamazepine, stiripentol, or quinidine * Has a medical condition that, in the opinion of the investigator, would limit the participant's ability to participate in the study or might compromise participant safety or interfere with evaluation of the study drug.

Primary outcome measure(s)

  • Part 1: Safety and tolerability of ABS-1230 (incidence and severity of adverse events) — Measured from Day 1 to End of Study or Early Termination (up to 12 weeks)
    Safety and tolerability of ABS-1230 by determining the incidence and severity of treatment emergent adverse events
  • Part 2: Efficacy of ABS-1230 — Measured from Day 1 to End of Study or Early Termination (up to 12 weeks)
    Percentage change from baseline in countable motor seizures (normalized per 28 days) as recorded in the seizure diary
  • Part 3: Safety and tolerability of ABS-1230 (incidence and severity of adverse events) — Measured from Day 1 of Part 3 to End of Study or Early Termination (up to 1 year)
    Safety and tolerability of ABS-1230 by determining the incidence and severity of treatment emergent adverse events

Trial sites (2)

FacilityCityRegionStatus
Northeast Regional Epilepsy Group Hackensack New Jersey Recruiting
University of Rochester Medical Center Rochester New York Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07600736 on ClinicalTrials.gov ↗ ← All trials in the USA